Because the consistent use of disease-modifying anti-rheumatic drugs ( DMARDs ) reduces long-term disability , we analysed the large database of 1817 RA patients from leflunomide trials to assess if changes in the Health Assessment Questionnaire ( HAQ ) can measure the effectiveness of RA therapy .
